Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Protect Children From The Allure Of Smoking, Say Doctors
BMA Scotland has warned that children who smoke face years of tobacco addiction that can lead to life-threatening diseases and premature death. The association also called on MSPs to support the proposals contained in the Tobacco and Primary Medical services (Scotland) Bill in order to reduce children"s exposure to tobacco products.

What Is The Risk Of Obesity While Taking Antidepressant Drugs?
Cross-sectional studies have reported an association between major depressive episode (MDE) and obesity. The objective of this longitudinal analysis was to determine whether MDE increase the risk of becoming obese over a 10-year period. Data from the Canadian National Population Health Survey (NPHS) were used, a longitudinal study of a representative cohort of household residents in Canada. The incidence of obesity, defined as a body mass index (BMI) of 30, was evaluated in respondents who were 18 years or older at the time of a baseline interview in 1994. MDE was assessed using a brief diagnostic instrument.
News of the day
Teenagers - Find Out If You're Healthy, Online Quiz
A free, online lifestyle self-assessment service to help teenagers improve their health and wellbeing is being rolled out nationally by the Department of Health today.
Medical Devices

Bosentan Is Cost-Effective For Patients With Moderate PAH

Bosentan appears to be a more cost-effective initial treatment option for patients with moderate pulmonary arterial hypertension (PAH), classified as WHO functional class III, than no active intervention. A cost-utility model was constructed to evaluate the cost-effectiveness of bosentan compared with no active intervention, both added to palliative care in the UK. In the model, simulated patients remained on their initial intervention until death or until they deteriorated to functional class IV, which triggered initiation of intravenous epoprostenol treatment. In the base-case analysis, which assumed that first line treatment did not affect survival, bosentan was more effective and less costly than no active intervention. When survival benefits associated with bosentan treatment were taken into consideration, bosentan was found to be a potential cost effective first line treatment. The work, led by Matt Stevenson was conducted at the University of Sheffield. Dr Stevenson commented: "Long-term follow-up data from randomised controlled trials show that bosentan significantly delays progression to more severe states compared with no active intervention. This results in both potential cost-savings due to a reduction in the duration of relatively expensive epoprostenol treatment and in an improvement in the quality of life for patients." This study is published in Value in Health, the official journal of the International Society for Pharmacoeconomics and Outcomes Research. Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research and help health care leaders to make decisions that are solidly evidence-based. The journal is published bi-monthly and has a regular readership of over 4,000 clinicians, decision-makers, and researchers worldwide. ISPOR is a nonprofit, international organization that strives to translate pharmacoeconomics and outcomes research into practice to ensure that society allocates scarce health care res wisely, fairly, and efficiently. ISPOR


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009